CGEM · Cullinan Therapeutics Inc. Common Stock
View on chartInsiders & Stakes
| Lynx1 Capital Management LP 10% Owner | ▲ Buy | Open Market | 8,963,500 Shares held | 10/28/2025 | View profile |
| Ansbert Gadicke Director | ▼ Sell | Open Market | 7,648,268 Shares held | 9/16/2021 | View profile |
| UBS Oncology Impact Fund L.P. 10% Owner | ▼ Sell | Open Market | 7,648,268 Shares held | 9/16/2021 | View profile |
| F2 Vision SCS 10% Owner | ▼ Sell | Open Market | 1,255,963 Shares held | 8/4/2022 | View profile |
| F2 Bioscience I 2017 Ltd 10% Owner | ▼ Sell | Open Market | 537,392 Shares held | 6/23/2022 | View profile |
| BVF PARTNERS L P/IL 10% Owner | ▼ Sell | Other | 392,808 Shares held | 1/19/2023 | View profile |
| Nadim Ahmed President and CEO | ▼ Sell | Open Market | 390,803 Shares held | 2/24/2026 | View profile |
| Savill Corrine Acting Chief Business Officer | ▲ Buy | Grant | 240,990 Shares held | 2/19/2025 | View profile |
| Jovan-Embiricos Morana 10% Owner | ▼ Sell | Tax Withholding | 207,803 Shares held | 6/24/2022 | View profile |
| Ebeling Thomas | ▲ Buy | Option Exercise | 186,653 Shares held | 6/10/2024 | View profile |
| Jeffrey Alan Jones Chief Medical Officer | ▼ Sell | Open Market | 159,968 Shares held | 2/24/2026 | View profile |
| Jennifer Michaelson See Remarks | ▼ Sell | Open Market | 158,844 Shares held | 9/8/2026 | View profile |
| Trigilio Jeffrey Chief Financial Officer | ▲ Buy | Grant | 133,919 Shares held | 2/22/2024 | View profile |
| Jacquelyn L. Sumer Chief Legal Officer | ▲ Buy | Grant | 130,559 Shares held | 6/30/2026 | View profile |
| Mary Kay Fenton Chief Financial Officer | ▲ Buy | Grant | 127,921 Shares held | 6/30/2026 | View profile |
| Baeuerle Patrick See Remarks | ▲ Buy | Grant | 76,000 Shares held | 2/17/2023 | View profile |
| Zawel Leigh See Remarks | ▲ Buy | Grant | 69,785 Shares held | 2/11/2022 | View profile |
| Keane Raymond T Chief Legal Officer | ▲ Buy | Grant | 24,124 Shares held | 2/11/2022 | View profile |
Transaction History
| Jennifer Michaelson | ▲ Buy | Option Exercise | 4,000 | $17K | 9/8/2026 |
| Jennifer Michaelson | ▼ Sell | Open Market | 8,000 | $173K | 9/8/2026 |
| Jennifer Michaelson | ▲ Buy | Option Exercise | 30,000 | $129K | 8/13/2026 |
| Jennifer Michaelson | ▼ Sell | Open Market | 30,000 | $608K | 8/13/2026 |
| Jennifer Michaelson | ▲ Buy | Option Exercise | 4,000 | $17K | 7/6/2026 |
| Jennifer Michaelson | ▼ Sell | Open Market | 8,000 | $143K | 7/6/2026 |
| Jacquelyn L. Sumer | ▲ Buy | Grant | 2,470 | $21K | 6/30/2026 |
| Mary Kay Fenton | ▲ Buy | Grant | 1,541 | $13K | 6/30/2026 |
| Jennifer Michaelson | ▲ Buy | Option Exercise | 4,000 | $17K | 5/5/2026 |
| Jennifer Michaelson | ▼ Sell | Open Market | 7,800 | $114K | 5/5/2026 |
| Jennifer Michaelson | ▼ Sell | Open Market | 200 | $3K | 5/5/2026 |
| Jennifer Michaelson | ▲ Buy | Option Exercise | 4,000 | $17K | 3/5/2026 |
| Jennifer Michaelson | ▼ Sell | Open Market | 8,000 | $125K | 3/5/2026 |
| Jennifer Michaelson | ▼ Sell | Open Market | 1,780 | $25K | 2/25/2026 |
| Jennifer Michaelson | ▼ Sell | Open Market | 3,601 | $52K | 2/24/2026 |
| Nadim Ahmed | ▼ Sell | Open Market | 13,515 | $196K | 2/24/2026 |
| Jeffrey Alan Jones | ▼ Sell | Open Market | 4,582 | $66K | 2/24/2026 |
| Jacquelyn L. Sumer | ▼ Sell | Open Market | 3,601 | $52K | 2/24/2026 |
| Jennifer Michaelson | ▼ Sell | Open Market | 1,752 | $25K | 2/23/2026 |
| Jeffrey Alan Jones | ▼ Sell | Open Market | 4,982 | $68K | 2/20/2026 |
| Jennifer Michaelson | ▼ Sell | Open Market | 3,742 | $51K | 2/20/2026 |
| Jennifer Michaelson | ▲ Buy | Option Exercise | 8,000 | $34K | 2/20/2026 |
| Jennifer Michaelson | ▼ Sell | Open Market | 8,000 | $114K | 2/20/2026 |
| Jacquelyn L. Sumer | ▼ Sell | Open Market | 3,742 | $51K | 2/20/2026 |
| Nadim Ahmed | ▼ Sell | Open Market | 16,381 | $223K | 2/20/2026 |
| Mary Kay Fenton | ▼ Sell | Open Market | 4,398 | $60K | 2/20/2026 |
| Mary Kay Fenton | ▲ Buy | Grant | 68,750 | $0 | 2/18/2026 |
| Jennifer Michaelson | ▲ Buy | Grant | 57,500 | $0 | 2/18/2026 |
| Jennifer Michaelson | ▼ Sell | Open Market | 416 | $5K | 2/12/2026 |
| Jennifer Michaelson | ▼ Sell | Open Market | 4,000 | $49K | 1/22/2026 |
| Mary Kay Fenton | ▲ Buy | Grant | 27 | $175 | 12/31/2025 |
| Nadim Ahmed | ▼ Sell | Open Market | 9,922 | $99K | 12/23/2025 |
| Jennifer Michaelson | ▼ Sell | Open Market | 1,345 | $13K | 12/19/2025 |
| Jacquelyn L. Sumer | ▼ Sell | Open Market | 3,480 | $34K | 12/18/2025 |
| Jeffrey Alan Jones | ▼ Sell | Open Market | 4,632 | $45K | 12/18/2025 |
| Jennifer Michaelson | ▼ Sell | Open Market | 2,898 | $28K | 12/18/2025 |
| Jennifer Michaelson | ▼ Sell | Open Market | 995 | $12K | 12/15/2025 |
| Jennifer Michaelson | ▼ Sell | Open Market | 2,148 | $27K | 12/12/2025 |
| Jennifer Michaelson | ▼ Sell | Open Market | 4,000 | $49K | 11/24/2025 |
| Lynx1 Capital Management LP | ▲ Buy | Open Market | 165,667 | $1.4M | 10/28/2025 |
| Lynx1 Capital Management LP | ▲ Buy | Open Market | 32,217 | $253K | 10/17/2025 |
| Lynx1 Capital Management LP | ▲ Buy | Open Market | 150,000 | $1.3M | 10/16/2025 |
| Lynx1 Capital Management LP | ▲ Buy | Open Market | 51,500 | $409K | 10/15/2025 |
| Lynx1 Capital Management LP | ▲ Buy | Open Market | 15,032 | $114K | 10/14/2025 |
| Lynx1 Capital Management LP | ▲ Buy | Open Market | 277,298 | $2.0M | 10/10/2025 |
| Lynx1 Capital Management LP | ▲ Buy | Open Market | 626,043 | $4.2M | 10/9/2025 |
| Lynx1 Capital Management LP | ▲ Buy | Open Market | 556,300 | $3.6M | 10/8/2025 |
| Jacquelyn L. Sumer | ▼ Sell | Open Market | 3,756 | $32K | 2/25/2025 |
| Jeffrey Alan Jones | ▼ Sell | Open Market | 4,895 | $42K | 2/25/2025 |
| Nadim Ahmed | ▼ Sell | Open Market | 12,529 | $107K | 2/25/2025 |
| Jennifer Michaelson | ▼ Sell | Open Market | 3,756 | $32K | 2/25/2025 |
| Jennifer Michaelson | ▲ Buy | Grant | 50,000 | $0 | 2/19/2025 |
| Savill Corrine | ▲ Buy | Grant | 37,500 | $0 | 2/19/2025 |
| Jacquelyn L. Sumer | ▲ Buy | Grant | 50,000 | $0 | 2/19/2025 |
| Nadim Ahmed | ▲ Buy | Grant | 180,000 | $0 | 2/19/2025 |
| Jeffrey Alan Jones | ▲ Buy | Grant | 65,000 | $0 | 2/19/2025 |
| Mary Kay Fenton | ▲ Buy | Grant | 60,000 | $0 | 2/19/2025 |
| Jennifer Michaelson | ▼ Sell | Open Market | 4,000 | $50K | 1/6/2025 |
| Nadim Ahmed | ▼ Sell | Open Market | 8,400 | $100K | 12/24/2024 |
| Jeffrey Alan Jones | ▼ Sell | Open Market | 4,632 | $53K | 12/18/2024 |
| Jacquelyn L. Sumer | ▼ Sell | Open Market | 3,482 | $40K | 12/18/2024 |
| Jennifer Michaelson | ▼ Sell | Open Market | 4,693 | $54K | 12/18/2024 |
| Jennifer Michaelson | ▼ Sell | Open Market | 3,489 | $44K | 12/12/2024 |
| Jennifer Michaelson | ▼ Sell | Open Market | 8,000 | $125K | 11/5/2024 |
| Jennifer Michaelson | ▼ Sell | Open Market | 8,000 | $145K | 9/5/2024 |
| Jennifer Michaelson | ▼ Sell | Open Market | 8,000 | $131K | 7/5/2024 |
| Jennifer Michaelson | ▲ Buy | Grant | 2,360 | $21K | 7/1/2024 |
| Ebeling Thomas | ▲ Buy | Option Exercise | 18,450 | $240K | 6/10/2024 |
| Ebeling Thomas | ▲ Buy | Grant | 84,224 | $362K | 5/23/2024 |
| Ebeling Thomas | ▲ Buy | Grant | 16,475 | $210K | 5/23/2024 |
| Jennifer Michaelson | ▲ Buy | Option Exercise | 5,606 | $24K | 5/7/2024 |
| Jennifer Michaelson | ▼ Sell | Open Market | 5,606 | $169K | 5/7/2024 |
| Jennifer Michaelson | ▲ Buy | Option Exercise | 50,000 | $215K | 5/6/2024 |
| Jennifer Michaelson | ▼ Sell | Open Market | 37,723 | $1.0M | 5/6/2024 |
| Jennifer Michaelson | ▼ Sell | Open Market | 20,277 | $579K | 5/6/2024 |
| Trigilio Jeffrey | ▲ Buy | Grant | 50,000 | $0 | 2/22/2024 |
| Nadim Ahmed | ▲ Buy | Grant | 160,000 | $0 | 2/22/2024 |
| Savill Corrine | ▲ Buy | Grant | 37,500 | $0 | 2/22/2024 |
| Jeffrey Alan Jones | ▲ Buy | Grant | 62,500 | $0 | 2/22/2024 |
| Jacquelyn L. Sumer | ▲ Buy | Grant | 50,000 | $0 | 2/22/2024 |
| Jennifer Michaelson | ▲ Buy | Grant | 50,000 | $0 | 2/22/2024 |
| Savill Corrine | ▲ Buy | Option Exercise | 40,000 | $172K | 2/1/2024 |
| Savill Corrine | ▼ Sell | Open Market | 40,000 | $647K | 2/1/2024 |
| Savill Corrine | ▼ Sell | Open Market | 40,000 | $564K | 1/29/2024 |
| Savill Corrine | ▲ Buy | Option Exercise | 40,000 | $172K | 1/29/2024 |
| Savill Corrine | ▼ Sell | Open Market | 21,316 | $266K | 1/23/2024 |
| Savill Corrine | ▲ Buy | Option Exercise | 21,316 | $92K | 1/23/2024 |
| Savill Corrine | ▲ Buy | Option Exercise | 14,559 | $63K | 1/22/2024 |
| Savill Corrine | ▼ Sell | Open Market | 14,559 | $177K | 1/22/2024 |
| Savill Corrine | ▼ Sell | Open Market | 4,125 | $50K | 1/22/2024 |
| Nadim Ahmed | ▼ Sell | Open Market | 4,272 | $39K | 12/26/2023 |
| Jeffrey Alan Jones | ▼ Sell | Open Market | 1,860 | $16K | 12/21/2023 |
| Jacquelyn L. Sumer | ▼ Sell | Open Market | 1,400 | $12K | 12/21/2023 |
| Trigilio Jeffrey | ▼ Sell | Open Market | 1,920 | $16K | 12/21/2023 |
| Jennifer Michaelson | ▼ Sell | Open Market | 1,145 | $10K | 12/21/2023 |
| Jeffrey Alan Jones | ▼ Sell | Open Market | 386 | $3K | 12/18/2023 |
| Jennifer Michaelson | ▼ Sell | Open Market | 238 | $2K | 12/18/2023 |
| Jacquelyn L. Sumer | ▼ Sell | Open Market | 290 | $2K | 12/18/2023 |
| Trigilio Jeffrey | ▼ Sell | Open Market | 398 | $3K | 12/18/2023 |
| Trigilio Jeffrey | ▼ Sell | Open Market | 1,926 | $15K | 12/12/2023 |
| Jennifer Michaelson | ▼ Sell | Open Market | 1,068 | $8K | 12/12/2023 |
| Trigilio Jeffrey | ▲ Buy | Grant | 2,340 | $21K | 6/30/2023 |
| Nadim Ahmed | ▼ Sell | Open Market | 759 | $9K | 6/28/2023 |
| Jeffrey Alan Jones | ▼ Sell | Open Market | 387 | $5K | 6/20/2023 |
| Jennifer Michaelson | ▼ Sell | Open Market | 238 | $3K | 6/20/2023 |
| Trigilio Jeffrey | ▼ Sell | Open Market | 399 | $5K | 6/20/2023 |
| Jacquelyn L. Sumer | ▼ Sell | Open Market | 291 | $4K | 6/20/2023 |
| Trigilio Jeffrey | ▼ Sell | Open Market | 319 | $4K | 6/12/2023 |
| Jennifer Michaelson | ▼ Sell | Open Market | 176 | $2K | 6/12/2023 |
| Jennifer Michaelson | ▲ Buy | Option Exercise | 100 | $430 | 6/7/2023 |
| Jennifer Michaelson | ▼ Sell | Open Market | 100 | $1K | 6/7/2023 |
| Jennifer Michaelson | ▲ Buy | Option Exercise | 11,900 | $51K | 6/6/2023 |
| Jennifer Michaelson | ▼ Sell | Open Market | 11,900 | $146K | 6/6/2023 |
| Nadim Ahmed | ▼ Sell | Open Market | 707 | $6K | 5/23/2023 |
| Jeffrey Alan Jones | ▼ Sell | Open Market | 394 | $3K | 5/18/2023 |
| Jacquelyn L. Sumer | ▼ Sell | Open Market | 291 | $3K | 5/18/2023 |
| Trigilio Jeffrey | ▼ Sell | Open Market | 399 | $3K | 5/18/2023 |
| Jennifer Michaelson | ▼ Sell | Open Market | 239 | $2K | 5/18/2023 |
| Jennifer Michaelson | ▼ Sell | Open Market | 193 | $2K | 5/12/2023 |
| Trigilio Jeffrey | ▼ Sell | Open Market | 347 | $3K | 5/12/2023 |
| Nadim Ahmed | ▼ Sell | Open Market | 716 | $8K | 4/25/2023 |
| Jennifer Michaelson | ▼ Sell | Open Market | 238 | $3K | 4/18/2023 |
| Jeffrey Alan Jones | ▼ Sell | Open Market | 392 | $4K | 4/18/2023 |
| Trigilio Jeffrey | ▼ Sell | Open Market | 398 | $4K | 4/18/2023 |
| Jacquelyn L. Sumer | ▼ Sell | Open Market | 290 | $3K | 4/18/2023 |
| Trigilio Jeffrey | ▼ Sell | Open Market | 318 | $3K | 4/12/2023 |
| Jennifer Michaelson | ▼ Sell | Open Market | 176 | $2K | 4/12/2023 |
| Nadim Ahmed | ▼ Sell | Open Market | 706 | $7K | 3/23/2023 |
| Trigilio Jeffrey | ▼ Sell | Open Market | 399 | $5K | 3/20/2023 |
| Jeffrey Alan Jones | ▼ Sell | Open Market | 390 | $4K | 3/20/2023 |
| Jennifer Michaelson | ▼ Sell | Open Market | 238 | $3K | 3/20/2023 |
| Jacquelyn L. Sumer | ▼ Sell | Open Market | 305 | $3K | 3/20/2023 |
| Nadim Ahmed | ▲ Buy | Grant | 109,000 | $0 | 2/22/2023 |
| Trigilio Jeffrey | ▲ Buy | Grant | 47,000 | $0 | 2/17/2023 |
| Savill Corrine | ▲ Buy | Grant | 20,500 | $0 | 2/17/2023 |
| Jacquelyn L. Sumer | ▲ Buy | Grant | 47,000 | $0 | 2/17/2023 |
| Baeuerle Patrick | ▲ Buy | Grant | 38,500 | $0 | 2/17/2023 |
| Jennifer Michaelson | ▲ Buy | Grant | 38,500 | $0 | 2/17/2023 |
| Jeffrey Alan Jones | ▲ Buy | Grant | 60,000 | $0 | 2/17/2023 |
| BVF PARTNERS L P/IL | ▼ Sell | Other | 300,000 | — | 1/19/2023 |
| BVF PARTNERS L P/IL | ▼ Sell | Other | 3,500,000 | — | 1/19/2023 |
| BVF PARTNERS L P/IL | ▼ Sell | Other | 2,600,000 | — | 1/19/2023 |
| Trigilio Jeffrey | ▲ Buy | Grant | 201 | $2K | 12/30/2022 |
| Jennifer Michaelson | ▼ Sell | Open Market | 4,000 | $53K | 11/25/2022 |
| Jennifer Michaelson | ▲ Buy | Option Exercise | 4,000 | $17K | 11/25/2022 |
| Jennifer Michaelson | ▲ Buy | Option Exercise | 4,000 | $17K | 9/27/2022 |
| Jennifer Michaelson | ▼ Sell | Open Market | 4,000 | $50K | 9/27/2022 |
| Jennifer Michaelson | ▲ Buy | Option Exercise | 1,385 | $6K | 8/8/2022 |
| Jennifer Michaelson | ▼ Sell | Open Market | 1,385 | $21K | 8/8/2022 |
| F2 Vision SCS | ▼ Sell | Open Market | 25,989 | $372K | 8/4/2022 |
| F2 Vision SCS | ▼ Sell | Open Market | 19,129 | $272K | 8/3/2022 |
| F2 Vision SCS | ▼ Sell | Open Market | 4,792 | $68K | 8/2/2022 |
| Jennifer Michaelson | ▲ Buy | Option Exercise | 8,000 | $34K | 7/25/2022 |
| Jennifer Michaelson | ▼ Sell | Open Market | 8,000 | $116K | 7/25/2022 |
| Savill Corrine | ▼ Sell | Open Market | 14,958 | $228K | 7/19/2022 |
| Savill Corrine | ▼ Sell | Open Market | 5,042 | $76K | 7/18/2022 |
| Savill Corrine | ▼ Sell | Open Market | 39,800 | $531K | 7/11/2022 |
| Savill Corrine | ▼ Sell | Open Market | 200 | $3K | 7/11/2022 |
| Jennifer Michaelson | ▲ Buy | Grant | 1,620 | $18K | 6/30/2022 |
| Trigilio Jeffrey | ▲ Buy | Grant | 1,451 | $16K | 6/30/2022 |
| Nadim Ahmed | ▲ Buy | Grant | 1,620 | $18K | 6/30/2022 |
| Jovan-Embiricos Morana | ▲ Buy | Option Exercise | 104,845 | $451K | 6/24/2022 |
| Jovan-Embiricos Morana | ▲ Buy | Option Exercise | 35,529 | $153K | 6/24/2022 |
| Jovan-Embiricos Morana | ▼ Sell | Tax Withholding | 45,078 | $604K | 6/24/2022 |
| F2 Bioscience I 2017 Ltd | ▼ Sell | Open Market | 29,631 | $385K | 6/23/2022 |
| F2 Bioscience I 2017 Ltd | ▼ Sell | Open Market | 49,953 | $635K | 6/22/2022 |
| F2 Bioscience I 2017 Ltd | ▼ Sell | Open Market | 22,319 | $285K | 6/21/2022 |
| Nadim Ahmed | ▲ Buy | Open Market | 8,090 | $100K | 6/6/2022 |
| BVF PARTNERS L P/IL | ▲ Buy | Open Market | 405,641 | $4.5M | 6/1/2022 |
| BVF PARTNERS L P/IL | ▲ Buy | Open Market | 301,009 | $3.3M | 6/1/2022 |
| BVF PARTNERS L P/IL | ▲ Buy | Open Market | 44,746 | $492K | 6/1/2022 |
| F2 Vision SCS | ▼ Sell | Open Market | 35,158 | $395K | 5/16/2022 |
| F2 Vision SCS | ▼ Sell | Open Market | 85,319 | $850K | 5/13/2022 |
| F2 Vision SCS | ▼ Sell | Open Market | 34,189 | $358K | 5/13/2022 |
| BVF PARTNERS L P/IL | ▲ Buy | Open Market | 53,598 | $490K | 5/13/2022 |
| BVF PARTNERS L P/IL | ▲ Buy | Open Market | 38,558 | $352K | 5/13/2022 |
| BVF PARTNERS L P/IL | ▲ Buy | Open Market | 17,744 | $162K | 5/13/2022 |
| F2 Vision SCS | ▼ Sell | Open Market | 264,072 | $2.4M | 5/12/2022 |
| BVF PARTNERS L P/IL | ▲ Buy | Open Market | 542,999 | $4.9M | 5/12/2022 |
| BVF PARTNERS L P/IL | ▲ Buy | Open Market | 457,001 | $4.1M | 5/12/2022 |
| BVF PARTNERS L P/IL | ▲ Buy | Open Market | 266,598 | $2.9M | 4/1/2022 |
| BVF PARTNERS L P/IL | ▲ Buy | Open Market | 9,402 | $101K | 4/1/2022 |
| Keane Raymond T | ▲ Buy | Grant | 22,500 | $0 | 2/11/2022 |
| Baeuerle Patrick | ▲ Buy | Grant | 37,500 | $0 | 2/11/2022 |
| Zawel Leigh | ▲ Buy | Grant | 32,500 | $0 | 2/11/2022 |
| Savill Corrine | ▲ Buy | Grant | 16,500 | $0 | 2/11/2022 |
| Trigilio Jeffrey | ▲ Buy | Grant | 37,500 | $0 | 2/11/2022 |
| Jennifer Michaelson | ▲ Buy | Grant | 28,500 | $0 | 2/11/2022 |
| F2 Vision SCS | ▼ Sell | Other | 1,187,734 | — | 1/11/2022 |
| Jennifer Michaelson | ▲ Buy | Option Exercise | 4,000 | $17K | 10/18/2021 |
| Jennifer Michaelson | ▼ Sell | Open Market | 3,396 | $72K | 10/18/2021 |
| Jennifer Michaelson | ▼ Sell | Open Market | 204 | $5K | 10/18/2021 |
| Jennifer Michaelson | ▼ Sell | Open Market | 400 | $9K | 10/18/2021 |
| Trigilio Jeffrey | ▲ Buy | Option Exercise | 8,000 | $34K | 10/15/2021 |
| Trigilio Jeffrey | ▼ Sell | Open Market | 8,000 | $200K | 10/15/2021 |
| Zawel Leigh | ▼ Sell | Open Market | 19,574 | $489K | 10/15/2021 |
| Zawel Leigh | ▼ Sell | Open Market | 1,079 | $27K | 10/7/2021 |
| Jennifer Michaelson | ▲ Buy | Option Exercise | 4,000 | $17K | 9/20/2021 |
| Jennifer Michaelson | ▼ Sell | Open Market | 3,200 | $78K | 9/20/2021 |
| Jennifer Michaelson | ▼ Sell | Open Market | 800 | $20K | 9/20/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Cullinan delays arthritis data update to December
Cullinan Therapeutics announced it will delay its arthritis data update for zipalertinib to December due to ongoing safety concerns. This decision follows the release of strong Phase 3 lung cancer data, which initially saw the stock drop 18.2%. The company also confirmed plans for Q4 2026 updates across three T cell engager programs.
Cullinan delays arthritis data update to December. Cullinan Therapeutics announced it will delay its arthritis data update for zipalertinib to December due to ongoing safety concerns. This decision follows the release of strong Phase 3 lung cancer data, which initially saw the stock drop 18.2%. The company also confirmed plans for Q4 2026 updates across three T cell engager programs.